Pictet Asset Management (UK)’s Aimmune Therapeutics AIMT Stock Holding History

Pictet Asset Management (UK)’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-281,679	Closed	-$4.71M	–	1587
2020 Q2	$4.71M	Buy	281,679 +15,847	+6%	+$269K	0.01%	701
2020 Q1	$3.83M	Buy	265,832 +96,700	+57%	+$2.47M	0.01%	713
2019 Q4	$5.66M	Buy	169,132 +9,090	+6%	+$254K	0.01%	733
2019 Q3	$3.35M	Buy	160,042 +94,043	+142%	+$1.92M	0.01%	789
2019 Q2	$1.37M	Buy	+65,999	New	+$1.36M	﹤0.01%	896
2016 Q3	–	Sell	-831,093	Closed	-$12.8M	–	862
2016 Q2	$12.8M	Buy	831,093 +738,593	+798%	+$10M	0.05%	383
2016 Q1	$1.48M	Hold	92,500	–	–	0.01%	728
2015 Q4	$1.71M	Buy	92,500 +15,900	+21%	+$294K	0.01%	741
2015 Q3	$1.94M	Buy	+76,600	New	+$1.79M	0.01%	730

Other funds holding AIMT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Pictet Asset Management (UK)'s AIMT Position: Q3 2020 in Review

Pictet Asset Management (UK) sold out of Aimmune Therapeutics (AIMT) in Q3 2020, closing a stake of 281,679 shares — an estimated $4.71M sold.

Pictet Asset Management (UK) first reported a position in AIMT in Q3 2015 and held it in 9 quarters. The position peaked at $12.8M in Q2 2016. 188 funds tracked by Wall St. Rank hold AIMT as of Q3 2020.

Pictet Asset Management (UK) reported no remaining Aimmune Therapeutics position as of Q3 2020 after selling out during the quarter.
Pictet Asset Management (UK) sold 281,679 Aimmune Therapeutics shares in Q3 2020, an estimated $4.71M.
Pictet Asset Management (UK) first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 9 quarters.
Pictet Asset Management (UK)'s Aimmune Therapeutics position peaked at $12.8M in Q2 2016.
188 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2020.

Based on Pictet Asset Management (UK)'s 13F filing for Q3 2020, filed 12 Nov 2020.